[HTML][HTML] Comprehensive review of potential drugs with anti-pulmonary fibrosis properties

J Ma, G Li, H Wang, C Mo - Biomedicine & Pharmacotherapy, 2024 - Elsevier
Pulmonary fibrosis is a chronic and progressive lung disease characterized by the
accumulation of scar tissue in the lungs, which leads to impaired lung function and reduced …

Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date

SJ Cassady, JAN Almario… - Drug, Healthcare and …, 2024 - Taylor & Francis
Pulmonary arterial hypertension (PAH) is a complex and incurable disease for which
pulmonary vasodilators remain the core therapy. Of the three primary pathways that …

[HTML][HTML] Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives

E Sciacca, G Muscato, L Spicuzza… - Multidisciplinary …, 2024 - ncbi.nlm.nih.gov
Idiopathic pulmonary fibrosis (IPF) represents a fibrotic interstitial lung disease characterized
by uncertain etiology and poor prognosis. Over the years, the path to effective treatments …

A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized …

X Wu, W Li, Z Luo, Y Chen - BMC Pulmonary Medicine, 2024 - Springer
Abstract Objective Randomized controlled trials (RCTs) of multiple drugs for Idiopathic
pulmonary fibrosis (IPF) have been reported and achieved a certain degree of efficacy …

Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular …

OA Shlobin, E Shen, SJ Wort, L Piccari… - Pulmonary …, 2024 - Wiley Online Library
Pulmonary hypertension (PH) due to interstitial lung disease (ILD), a commonly encountered
complication of fibrotic ILDs, is associated with significant morbidity and mortality. Until …

A PrOsPective Cohort Study on Interstitial Lung Disease-Associated Pulmonary Hypertension with a ParticulaR Focus on the Subset with Pulmonary Arterial …

I Tsujino, K Kitahara, J Omura, T Iwahori, S Konno - Pulmonary Therapy, 2024 - Springer
Introduction The pathogenesis and clinical profiles of patients with pulmonary hypertension
(PH) associated with interstitial lung disease (ILD-PH) are poorly understood. Whether and …

[HTML][HTML] A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors

AS Poklepovic, SW Gordon, S Kothadia… - Anti-Cancer …, 2024 - journals.lww.com
The purpose of this study is to establish the recommended phase 2 dose for regorafenib in
combination with sildenafil for patients with advanced solid tumors. Secondary outcomes …

Exploring the role and association of monocytes with progression of Idiopathic Pulmonary Fibrosis

AKN Achaiah - 2024 - eprints.soton.ac.uk
Idiopathic pulmonary fibrosis (IPF) is a chronic fibroproliferative disease characterised by
accumulation of scar tissue within the lung parenchyma. The clinical course of IPF is …

Investigating the role of phosphodiesterases in myofibroblast transformation in Peyronie's disease

S Harding - 2024 - aru.figshare.com
Introduction: Peyronie's disease (PD) is characterised by a fibrous plaque that forms in the
penile tunica albuginea (TA), leading to pain, penile deformity, and erectile dysfunction …

The Effect of Phosphodiesterase-5 Inhibitor on Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis, A Single Centre Study

BA NAGLAA, AA AHMED, HM HOSAM… - … Medical Journal of …, 2024 - mjcu.journals.ekb.eg
Abstract Background: Pulmonary hypertension (PH), group III of the international aetiological
classification, is a frequent and severe complication of interstitial lung diseases (ILDs), espe …